Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
SAN DIEGO and TORONTO, Feb. 18, 2016 -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will present at the 2016 RBC Capital Markets Global Healthcare Conference at 10:00 a.m. ET on Wednesday, February 24, 2016 in New York City.
A live webcast of the fire-side chat can be accessed by visiting:
http://www.veracast.com/webcasts/rbc/healthcare2016/74205320763.cfm
The audio webcast will be archived shortly after the live event and will be available for 30 days through the Aptose website at www.aptose.com.
About Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer research coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed to provide additive or synergistic efficacy with existing anti-cancer therapies and regimens without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS. For further information, please visit www.aptose.com.
For further information, please contact: Aptose Biosciences Inc. Greg Chow, CFO 647-479-9828 [email protected] BCC Partners Karen L. Bergman or Susan Pietropaolo 650-575-1509 or 845-638-6290 [email protected] or [email protected]
